0001136261-22-000155.txt : 20220304
0001136261-22-000155.hdr.sgml : 20220304
20220304160213
ACCESSION NUMBER: 0001136261-22-000155
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220228
FILED AS OF DATE: 20220304
DATE AS OF CHANGE: 20220304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Golembiewski Michael Joseph
CENTRAL INDEX KEY: 0001639479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22245
FILM NUMBER: 22713981
MAIL ADDRESS:
STREET 1: 7 TURTLE CT
CITY: FLEMINGTON
STATE: NJ
ZIP: 08822
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001017491
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870449967
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (646) 293-2100
MAIL ADDRESS:
STREET 1: 300 PARK AVENUE
STREET 2: 2ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC.
DATE OF NAME CHANGE: 20100914
FORMER COMPANY:
FORMER CONFORMED NAME: NEXMED INC
DATE OF NAME CHANGE: 19970311
4
1
ownership.xml
X0306
4
2022-02-28
0
0001017491
SEELOS THERAPEUTICS, INC.
SEEL
0001639479
Golembiewski Michael Joseph
C/O SEELOS THERAPEUTICS, INC.
300 PARK AVENUE, 2ND FLOOR
NEW YORK
NY
10022
0
1
0
0
Chief Financial Officer
Common Stock
2022-02-28
5
A
0
E
12500
0.901
A
78487
D
These shares were acquired under the Company's 2020 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
/s/ Michael Golembiewski
2022-03-04